The role of bariatric surgery has grown significantly over the past decade, with an additional 10,000 procedures performed per year from 2011 to 2015, and an increase of 20,000 procedures from 2015 to 2016 in the USA \[[@CR1]\]. In particular, gastric bypass, sleeve gastrectomy, adjustable gastric banding and biliopancreatic diversion with duodenal switch are frequently performed. These procedures are associated with significant long-term weight loss as well as alterations in gut hormone production and metabolism that suppress appetite and promote satiety. However, weight regain following primary bariatric surgery remains an ongoing problem. It is estimated that clinically significant weight regain occurs in up to one-third of patients \[[@CR2]--[@CR6]\] who have undergone a Roux-en-Y gastric bypass (RYGB) or vertical banded gastroplasty (VBG).

There are several factors that weight regain post-RYGB can be attributed to; notably a combination of lifestyle, mental health, hormonal/metabolic and surgical factors. Thus, the need to understand and address these issues with patients in the pre- and post-operative stage is crucial in preventing the reemergence of obesity related comorbidities and impaired quality of life \[[@CR7], [@CR8]\]. Non-surgical management of weight regain following bariatric surgery requires the input of the multidisciplinary team. Despite this, a proportion of patients still experience weight regain following bariatric surgery \[[@CR9]\]. Dilatation of the gastrojejunal anastomosis or the gastric pouch is a well-recognised post-operative occurrence. On the basis that gastric pouch size, distension and transit time following RYGB is a surgical mechanism for early satiety and weight loss, this post-operative event may reduce the restrictive and malabsorptive effects of RYGB. Surgical revision of the gastrojejunal anastomosis is controversial as most patients are exposed to major post-operative complications, higher readmission rates and morbidity \[[@CR9]\] but do not achieve significant weight reduction \[[@CR10], [@CR11]\].

Hence, endoluminal revision procedures have been developed to address this gap. These techniques come in various forms: endoluminal plication devices and other techniques like sclerotherapy, mucosal ablation and argon plasma coagulation. Endoluminal plication devices work by taking superficial or full-thickness bites of the intraluminal pouch mucosa or at the gastrojejunal anastomosis. Sutures or clips are then deployed via endoscope. Meanwhile, other techniques like sclerotherapy, mucosal ablation and APC induce scarring at the gastrojejunal anastomosis thus reducing its size. As the number of patients undergoing bariatric surgery continues to grow, the need to consider endoluminal revision procedures becomes increasingly important. Thus, this systematic review aims to assess efficacy of endoluminal techniques that attempt to revise primary bariatric procedures.

Methods {#Sec2}
=======

Criteria for considering studies for this review {#Sec3}
------------------------------------------------

All published studies that utilised endoluminal or endoscopic techniques following primary bariatric surgery were evaluated. Inclusion criteria are as follows: (a) studies investigating patients who had undergone endoscopic procedures following a primary bariatric surgery procedure (b) weight regain after surgery (c) presence or recurrence of comorbidities (d) post-operative complications (e) presence of anatomical cause for weight regain. Exclusion criteria are as follows: studies that did not include revision surgery, endoluminal procedures used in the management of complications following primary surgery, articles that assess primary bariatric surgery, non-endoluminal interventions, review articles, studies not written in the English language, animal studies, comment, opinions or letters, case reports and technical articles with no evidence of patient follow-up post-procedure, and conference abstracts.

Literature search {#Sec4}
-----------------

The following databases were searched: (a) Medline (1946---present) via OvidSP, (b) MEDLINE Epub ahead of print, in process and other non-indexed citations (latest issue via Ovid SP, last search 19th July 2019); (c) Ovid Embase (1947---19th July 2019). Additionally, all references of included articles were manually reviewed to identify additional studies. Three strings were utilised; these terms were "bariatric surg\*.mp. OR metabolic surg\*.mp. OR weight loss surg\*.mp.", "revision\*".mp., "endoscopic procedure.mp. OR endosco\*.mp." and truncated search terms using wild card character and "related articles" function were used to broaden search. The references of included articles were also hand-searched to identify any additional studies.

Data extraction and outcome measures {#Sec5}
------------------------------------

Two independent reviewers (YMG, NEJ) screened all titles and abstract manually for inclusion. A third reviewer (ELG) was consulted in the case of a disagreement. Relevant data were entered into Review manager 5.4 (Cochrane Collaboration, Oxford, United Kingdom). The following data items were extracted: year of publication, country of origin, study design, number of participants, type of primary procedure, type of endoluminal procedure performed, patient demographics, mean time since initial procedure, selection criteria in each study, mean pre-revision weight and BMI, mean weight loss post-procedure, complications post-procedure, average length of procedure, average stoma diameter at the end of the procedure, excess weight loss, length of follow-up and number of successful endotherapy.

Quality assessment {#Sec6}
------------------

Studies were appraised for rigorousness in methodology using the Newcastle--Ottawa Quality Assessment Scale \[[@CR12]\] and risk of bias assessed using the National Institute of Health (NIH) Quality Assessment Tool for Case Series Studies \[[@CR13]\].

Results {#Sec7}
=======

Twenty-six studies comprising a total of 1835 patients who had undergone endoluminal procedure following initial primary bariatric procedure were included in this study (Fig. [1](#Fig1){ref-type="fig"}). Endoluminal plication devices were used in 1087 patients, other techniques in 721 patients, and a combination of the two types of procedures in 27 patients. All studies were published over a period of twelve years from 2007 to 2019. There were eight prospective case series and one prospective multicentre randomised control trial. Of the 26 studies, 19 were performed in USA, one in Brazil, two in centres located in USA and Brazil, one in Belgium, one in France and one in Canada. Mean age of patients included in the review was 51.5 years old (range 22.0--71.4 years). The mean time since initial bariatric procedure was 86.7 months (range 12.0--222 months) (Table [1](#Tab1){ref-type="table"}).Fig. 1PRISMA chart of the study selection processTable 1Patient and study demographicsStudyCountryStudy typeNoPrimary OperationProcedureM:FMean age (years)Mean time since initial procedure (months)Selection criteriaMean pre-revision weight (kg)Mean pre-revisionBMI (kg/m^2^)Mikami et al. \[[@CR14]\]USARetro case series39RYGBStomaphyX™3:3647.8 (29--64) \> 2 years post-op \> 10% of nadir weight108 (65.9--172.2)39.8 (22.7--63.2)Manouchehri et al. \[[@CR26]\]CanadaPros case series14Vertical Banded GastroplastyStomaphyX™1:1347.3 ± 7.9116.4 ± 73.2Persistent WG119.5 ± 25.943.4 ± 9.7Ong\'Uti et al. \[[@CR15]\]USARetro case series27RYGBStomaphyX™2:2549 (44--54)72 (60--96) \> 2 years post-op103 (88.5--115)\*\*37 (32--40)Goyal et al. (39)USARetro case series55RYGBStomaphyX™1:5349.6 (30--68)68.4 (12--156)96.636.1Mullady et al. \[[@CR29]\]USAPros case series20RYGBROSE1:1948 (36--62)63 (24--117)WR/ no WL, satiety36.7 (28,4--48.8)Horgan et al. \[[@CR18]\]USAPros case series116RYGBROSE via Incisionless Operating Platform (IOP)15:10145.6 ± 8.7 \> 2yrs post-op, \> 50% EWL after RYGB110.8 ± 20.539.9 ± 6.7Ryou et al. \[[@CR30]\]USAPros case series5RYGBROSE0:548 (41--55)56 (24--76)WR, satiety, dilated pouch/ GJA100.436.3Gallo et al. \[[@CR17]\]USARetro case series27RYGBROSE2:2549.2 ± 9.6 (26--68)142.8 ± 51.6 \> 50% EWL, sig WG 2 years post-op106.2 ± 21.2\*\*40.6 (30--67)Buttelmann et al. \[[@CR31]\]USARetro case series8RYGBROSE48Inadequate/ failure to lose weight43.7Thompson et al. \[[@CR18]\]USARetro case series116RYGBIOP15:10146 ± 9 \> 2yrs after RYGB110.5 ± 20.539.9 ± 6.7Heylen et al. \[[@CR27]\]BelgiumPros case series46TVGBOTSC-clip19:75 \> 10% WG 2yrs post-op, reappearing comorbidities, volume/ frequency of meals32.8Patel et al. \[[@CR32]\]USARetro case series50RYGBEGJRIST- 2:32IST 48.6 ± 10.3IST 115.2 ± 39.6WR \> 2yrs, stoma dilation \> 15 mmIST 114.5 ± 20.5IST 41/7 ± 6/4PST- 2:14PST 55.8 ± 10.8PST 114 ± 42PST 110.2 ± 22.6PST 40.7 ± 8.7Tsai et al. \[[@CR22]\]SwitzerlandRetro case series81RYGBEGJR (OverStitch device)22:5948.0 (26.8--71.4)84 (12--222) \> 15 kg increase from nadir weight, 10 kg increase within 6--12 months post-op127.1 (96--225)44.7 (35.3--67)Catalano et al. \[[@CR33]\]USARetro case series28RYGBSclerotherapy (sodium morrhuate)10:1841.1 (27--58)Stoma size \> 1.2 cm, WR after RYGB112Loewen and Barba \[[@CR34]\]USARetro case series71RYGBSclerotherapy (sodium morrhuate)4:6745 (30--64)34.8 (34.8--66 \> 5% WG, inadequate WL \< 50% EWL98.1 ± 21.6\*\*35.5Jirapinyo et al. \[[@CR24]\]USAPros case series43RYGBSclerotherapy (sodium morrhuate) (34)3:3147 ± 972 ± 60 \> 1 yr post-op \> 20% of nadir weightTORe (9)1:847 ± 1384 ± 48Thompson et al. \[[@CR21]\]USAPros, multicentre RCT50RYGBTORe3:4747.6 ± 9.4658BMI 30--60 at \> 6 months post-op, Inadequate WL \> 50% EWL/ WR \> 5% EWL, GJA \> 2 cm101.5 ± 16.437.6 ± 4.9de Moura et al. \[[@CR39]\]USARetro case report1RYGBTORe0:15514473.35\*\*27.9Kumar and Thompson \[[@CR37]\]USARetro case series59RYGBST TORe3:5648.8 ± 1.1Stoma diameter \> 20 mm40.4 ± 1.059FT TORe15:4449.9 ± 1.341.1 ± 1.3Kumar and Thompson \[[@CR36]\]USAPros case series150RYGBTORe (OverStitch device)27:12351.2 ± 0.8103.2 ± 3.6GJA \> 15 mm110.7 ± 2.240.1 ± 0.7Jirapinyo et al. \[[@CR25]\]USARetro case series25RYGBTORe (OverStitch device)7:1848 (34--69)72 (24--120)WR, GJA \> 15 mm43Vargas et al. \[[@CR23]\]USA, BrazilRetro case series130RYGBTORe (OverStitch device)16:11447.12 ± 8.55100.8 ± 57.4WR36.8 ± 6.84Baretta et al. \[[@CR20]\]BrazilPros case series30RYGBAPC4:2642.83 (22--59) \> 18 months post-op, regain of \> 10% of nadir weight, stoma diameter \> 15 mm121.77 ± 22.5045.63 ± 7.63Moon et al. \[[@CR19]\]USA, BrazilRetro case series558RYGBAPC103:45540.9 ± 9.590 (60, 120)\* \> 18 months post-op, regain of \> 10% of nadir weight, satiety, size of GJ stoma \> 15 mm94.5 ± 18.634.0 ± 5.7Riva et al. \[[@CR35]\]FranceRetro case series22RYGBMucosal ablation + endoscopic suturing (OverStitch device) (11)5:1752.2 ± 11.7106.8 ± 99.6Sig WG \> 50%104.3 ± 27.442.4 ± 9.05Mucosal ablation + endoscopic suturing + sclerotherapy (OverStitch device) (11)100.3 ± 27.042.4 ± 10.4Eid \[[@CR28]\]USARetro case series5LSGAPC + endoscopic suturing (OverStitch device)4:159.2 (48--63)37.4 (32.2--48.2)WR110.25 (85.05--130.50)\*\*37StudyMean post-surgical weight (kg)Mean post-revision BMI (kg/m2)Complication post-procedure3 months6 months1 year2 years3 years3 months6 months1 year2 years3 yearsMikami et al. \[[@CR14]\]101.399.398Minor: sore throat (87.1), epigastric pain (76.9)Manouchehri et al. \[[@CR26]\]109.6 ± 24.4 (4 months)39.8 ± 9.1 (4 months)Minor headache, back painOng\'Uti et al. \[[@CR15]\]101.394.593.9 (81.6 ± 102)\*\*33 (29--36) (0 months)Goyal et al. (39)92.9 (1 month)92.894.9NilMullady et al. \[[@CR29]\]Minor: abdominal bloating, mild sore throatsHorgan et al. \[[@CR18]\]103Mild: pharyhgitis 48 (41), Nausea/vomiting 14 (12), Abdo pain 13 (11) Moderate: superficial distal oesophagus tear 3(2.9)Ryou et al. \[[@CR30]\]92.633.4NilGallo et al. \[[@CR17]\]39.2 ± 739.9 ± 10.137.7 ± 6.3NilButtelmann et al. \[[@CR31]\]40.640.73938.9NilThompson et al. \[[@CR18]\]104.6Heylen et al. \[[@CR27]\]29.727.4Mild: sore throat Moderate: 5(10.9) dysphagia (repeat OGD), 2 persistent dysphagia had endoscopic dilatation)Patel et al. \[[@CR32]\]Tsai et al. \[[@CR22]\]122.6121.1119.1NilCatalano et al. \[[@CR33]\]92.1 (18 month)Mild: 21 (75) post-injection pain. Moderate: 10 (35.7) shallow circumferential ulcers at stomaLoewen and Barba \[[@CR34]\]Jirapinyo et al. \[[@CR24]\]Pain 1, heartburn 1, hypertensive urgency 1, bleeding 1Pain 2Thompson et al. \[[@CR21]\]95.1 ± 15.22Mod: gastric mucosal tear, pulmonary oedemade Moura et al. \[[@CR39]\]55.8\*\*49.5\*\*21.2\*\*18.8\*\*NilKumar and Thompson \[[@CR37]\]Bleeding 1Bleeding 1Kumar and Thompson \[[@CR36]\]101.1100.1100.290.791.536.636.336.336.836.7Pain 6 (4.0), bleeding 5 (3.3), nausea 3 (2.0)Jirapinyo et al. \[[@CR25]\]Hematemesis 1, delayed GI bleeding 1, nausea 4, severe emesis with torn stitches 2, stenosis of GJA 1Vargas et al. \[[@CR23]\]Nausea 18 (14), Pain 23 (18), Oesophageal tear requiring endoscopic clipping 1 (\< 1), balloon dilation of narrowed GJA after TORe 5 (4)Baretta et al. \[[@CR20]\]83.29 (4 months)78.8731.14 ± 5.81Severe stenosis (stoma diameter \< 3 mm) 2, ulcers at stoma 10Moon et al. \[[@CR19]\]Stenosis 9, GJ ulcer 3, vomiting 3, GJ leakage 2, melena 1Riva et al. \[[@CR35]\]3634Minor: nausea and mild abdominal pain (44)Eid \[[@CR28]\]100.08 (75.15--121.5)\*\*98.1 (72.9--119.25)\*\*99.09 (74.25--119.7)\*\*33.64 (26.7--44.9)Key: \* median value, interquartile range, \*\* conversion from lb to kg (1 lb = 0.45)*EWL* excess weight loss, *ROSE* restorative obesity surgery, endoluminal (ROSE) procedure, *EGJR* endoscopic gastrojejunal revision, *RYGB* Roux-en-Y gastric bypass, *LSG* laparoscopic sleeve gastrectomy, *OTSC-clip* over-the-scope clip, *IOP* incisionless operating platform, *TORe* sutured transoral outlet reduction, *ST* superficial-thickness, *FT* full-thickness, *APC* argon plasma coagulation, *Pros* prospective, retro: retrospective, *GJA* gastrojejunal anastomosis, *WR* weight regain, *WL* weight loss, *WG* weight gain, *EWL* excess weight loss

Twenty-five of the 26 included studies had clear selection criteria for all patients included in their study. These are as follows:Greater than 18 months following initial bariatric procedure \[[@CR14]--[@CR20]\]Weight regain or failure to lose sufficient weight \[[@CR17], [@CR19]--[@CR35]\]Aged between 18 to 65 years old \[[@CR16], [@CR18], [@CR32]\]Decreased satiety \[[@CR19], [@CR29], [@CR30]\]Dilated gastrojejunal anastomosis and gastric pouch \[[@CR19]--[@CR21], [@CR25], [@CR30], [@CR32], [@CR33], [@CR36], [@CR37]\]Increased volume / frequency of meals \[[@CR27]\]Reappearing comorbidities \[[@CR27]\]BMI 30--60 kg/m^2^ greater than six months after RYGB \[[@CR21]\]

One study \[[@CR38]\] did not detail the inclusion nor exclusion criteria in patient selection.

Endoluminal bariatric procedures {#Sec8}
--------------------------------

The endoluminal procedures identified were (i) endoluminal plication devices e.g. StomaphyX™, Restorative Obesity Surgery Endoluminal (ROSE) procedure, Incisionless Operating Platform (IOP), Over-The-Scope Clip (OTSC-Clip), e.g. sutured Transoral Outlet Reduction (TORe), Endoscopic Overstitch device and Endoscopic Gastrojejunal Revision (EJGR) and (ii) other techniques e.g. sclerotherapy, mucosal ablation, and Argon Plasma Coagulation (APC). Initial bariatric procedures performed were the roux-en-Y gastric bypass (RYGB), transected vertical gastric bypass (TVGB), vertical banded gastroplasty (VBG) and laparoscopic sleeve gastrectomy (LSG) (Tables [1](#Tab1){ref-type="table"},[2](#Tab2){ref-type="table"}).Table 2Roux-en-Y Gastric Bypass (RYGB)StudyProcedureCombination therapy (Y/N)Av. procedure length (mins)Av. stoma diameter at end of procedure (mm)% Excess weight loss1 week1 month2 months3 months6 months12 monthsMikami \[[@CR14]\]StomaphyX™N35 (16--62)(2 weeks)7.410.613.113.117.019.5Ong-Uti \[[@CR15]\]StomaphyX™N20 (20--30)(2 weeks)24334720Goyal \[[@CR38]\]StomaphyX™N24.1 (10--55)12.87.3 ± 7.111.6 ± 12.111.5 (17.9)Mullady et al. \[[@CR29]\]ROSEN103 (50--154)5.8 kg\*8.8 kg\*\*Horgan et al. \[[@CR16]\]IOPN8711.521.5 ± 15.3Ryou et al. \[[@CR30]\]ROSEN80 (60--100)4.2 kg\*\*7.8 kg\*\*Gallo et al. \[[@CR17]\]ROSEN77 ± 308 ± 48.99.38Buttelmann \[[@CR31]\]ROSEN3.9\*\*\*4.1\*\*\*5.4\*\*\*Thompson \[[@CR18]\]IOPN8711.514.5 ± 3.1Patel 2017 \[[@CR32]\]EGJRNIST 50.4 ± 25.3IST 6.6 ± 2.26 weeks\*15 (9--22)19 (9--27)\*13 (5--32)\*10 (− 3.2 to 23.1)PST 42.9 ± 18.1PST 4.8 ± 1.8Tsai \[[@CR22]\]EGJRN17.2 (12--33)6 (4--14)4.1\*\*5.8\*\*8.0\*\*Catalano \[[@CR33]\]SclerotherapyN10 (8--15)10.4Loewen and Barba \[[@CR34]\]SclerotherapyNJirapinyo \[[@CR24]\]Sclerotherapy (sodium morrhuate)N21 ± 62.7 ± 5.5\*\*\*\*6.1 ± 6.8 (9 months)\*\*\*\*TORe23 ± 610.4 ± 2.2\*\*\*\*12.3 ± 12.6 (9 months)\*\*\*\*Thompson \[[@CR21]\]TOReN107 ± 182.915.9de Moura \[[@CR40]\]TOReN1220\*\*14\*\*Kumar and Thompson \[[@CR37]\]ST TOReN6.9 ± 0.28.1 ± 2.59.1 ± 2.3FT TORe7.1 ± 0.320.4 ± 3.318.9 ± 5.4Kumar and Thompson \[[@CR36]\]TORe (OverStitch)N9.0 ± 0.225.0 ± 1.928.8 ± 2.724.9 ± 2.6Jirapinyo \[[@CR25]\]TORe (OverStitch)N27 (7--80)6 (3--10)11.5\*\*11.7\*\*10.8\*\*Vargas \[[@CR23]\]TORe (OverStitch)N9.31 ± 6.720.2 ± 10Baretta \[[@CR20]\]APCN8.40 ± 1.85Moon \[[@CR19]\]APCN(5--10)14.0 ± 6.36.5\*\*7.7\*\*Riva \[[@CR35]\]OverStitch + suturingY91 ± 72.49.05OverStitch + sclerotherapyStudy% Excess weight lossRecurrence rates n (%)Definition of successful endotherapyNumber of successful endotherapy n (%)18 months24 months36 months48 months60 months72 monthsMikami \[[@CR14]\]Ong-Uti \[[@CR15]\]3 (4.7%)Goyal \[[@CR38]\]4.3 ± 29.82 (3.6)--progressed to further procedure1. Ability to reduce pouch and stoma size2. Weight loss35 (63.6)Mullady et al. \[[@CR29]\]1. Ability to reduce stoma diameter and pouch length2. Weight loss17 (85)Horgan et al. \[[@CR16]\]1. Ability to reduce stoma diameter and pouch length2. Weight loss112 (97)Ryou et al. \[[@CR30]\]1. Ability to reduce stoma diameter and pouch length2. Weight loss5 (100)Gallo et al. \[[@CR17]\]6.7 − 10.7 − 13.5 − 5.8 − 4.5Buttelmann \[[@CR31]\]5.5\*\*\*Thompson \[[@CR18]\]1. Ability to reduce stoma diameter and pouch length2. Weight loss112 (97)Patel 2017 \[[@CR32]\]IST 3 (8.8)PST 0Tsai \[[@CR22]\]Catalano \[[@CR33]\]19.91. Stoma size \< 12 mm2. Loss of \> 75% of weight regained after initial weight loss18 (64)Loewen and Barba \[[@CR34]\]2nd session 35 (49), 3rd session 10(14), 4th session 1(1.4)21 (29.6)Jirapinyo \[[@CR24]\]Ability to reduce the GJ to \< 12 mmThompson \[[@CR21]\]Ability to reduce the GJ to \< 10 mm89.6%de Moura \[[@CR40]\]Weight maintenance/ weight loss24 (29.6)Kumar and Thompson \[[@CR37]\]Kumar and Thompson \[[@CR36]\]20.0 ± 6.419.2 ± 4.6Jirapinyo \[[@CR25]\]Ability to reduce the GJ to \< 12 mm25 (100)Vargas \[[@CR23]\]8 ± 8.8 (18--24mths)11 (8)---repeat EGD performedAbility to reduce the GJ to \< 10 mmBaretta \[[@CR20]\]Moon \[[@CR19]\]8.3\*\*Riva \[[@CR35]\]36.4Key: \* median value, interquartile range, \*\* mean weight loss, \*\*\* mean BMI loss, \*\*\*\* mean %TBWL*TBWL* total body weight loss, *EWL* excess weight loss, *ROSE* restorative obesity surgery, endoluminal (ROSE) procedure, *EGJR* endoscopic gastrojejunal revision, *RYGB* Roux-en-Y gastric bypass, *OTSC-clip* over-the-scope clip, *IOP* incisionless operating platform, *TORe* sutured transoral outlet reduction, *GJA* gastrojejunal anastomosis, *APC* Argon plasma coagulation

Weight loss {#Sec9}
-----------

Excess weight is defined as the difference between the patient's actual weight and ideal weight. The percentage excess weight loss (EWL) is defined as the proportion of weight loss after endoluminal procedures divided by the difference of regained weight from nadir weight.

Revision surgery using endoluminal plication devices were performed in 18 studies post-RYGB \[[@CR14]--[@CR18], [@CR21]--[@CR25], [@CR29]--[@CR32], [@CR36]--[@CR39]\]. Results of these studies were analysed together. Of these, Stomaphyx™ was performed in three studies \[[@CR14], [@CR15], [@CR38]\], ROSE in five studies \[[@CR16], [@CR17], [@CR29]--[@CR31]\], IOP in one study \[[@CR18]\], TORe in seven studies \[[@CR21], [@CR23]--[@CR25], [@CR36], [@CR39]\] and EJGR in two studies \[[@CR22], [@CR32]\]. These procedures were performed a mean of 91.2 months (12.0--222 months) after RYGB. Mean pre-revision weight was 105.6 kg (65.9--225 kg). Mean weight loss (6.27 kg) was greatest within the first 3 months post-procedure. This weight loss was sustained for up to two years after the revision endoluminal procedure. Post-procedure BMI within the first three months after the revision procedure had decreased by a mean of 7.61%, but there are insufficient data to comment on mean post-procedure BMI after two years. Mean EWL was sustained at 19.3% six months following the initial procedure. However, this was not maintained in patients two years post-procedure (EWL 10.3%).

There were two studies in which endoluminal procedures were performed in patients following VBG and TVGB, respectively \[[@CR26], [@CR27]\]. One study utilised the StomaphyX™ for revision of VBG \[[@CR26]\]. The authors demonstrated a weight reduction of 9.9 kg at four months post-revisional procedure, with a decrease in BMI of 3.6 kg/m^2^ (8.28% weight loss) over the same time period \[[@CR26]\]. The other study reported a mean decrease in BMI of 3.1 kg/m^2^ (9.45% weight loss) following the use of the OTSC-clip at 3 months post-revisional procedure in a group of TVGB patients \[[@CR27]\]. This was sustained at 7.01% at 12 months post-revisional procedure. On review of both papers, neither study had reported the EWL following endoluminal revision surgery.

All endoluminal plication devices post-RYGB showed a mean overall decrease in EWL over the first three months of 13.9% \[[@CR14]--[@CR18], [@CR21]--[@CR25], [@CR29]--[@CR32], [@CR36]--[@CR39]\]. This EWL was sustained at 13.7% at the 12-month follow-up (Fig. [2](#Fig2){ref-type="fig"}). Following this, the percentage EWL after 12 months post-procedure is demonstrated to show a steady decline to 8.5% 36 months post-procedure. Endoluminal plication devices were shown to be successful in 91.8% of patients in studies which provided data. Definitions of success in the various procedures are outlined where data are available (Table [2](#Tab2){ref-type="table"}). These include the ability to reduce the diameter of the gastrojejunal stoma and pouch length \[[@CR16], [@CR18], [@CR21], [@CR23], [@CR25], [@CR29], [@CR30], [@CR38]\], as well as weight loss post-procedure \[[@CR16], [@CR18], [@CR29], [@CR30], [@CR38], [@CR39]\]. Recurrence rates and need for further procedure following endoluminal plication devices were 5.02%.Fig. 2Graph demonstrating percentage EWL over time in endoluminal plication devices and others (sclerotherapy and APC)

Meanwhile, the other techniques used post-RYGB i.e. sclerotherapy and APC showed a much lower weight loss compared to endoscopic plication devices with a 3.87% EWL three months post-procedure \[[@CR19], [@CR20], [@CR24], [@CR33], [@CR34]\]. A 19.9% EWL at 18 months post-procedure is reported in Catalano et al.'s study utilising sclerotherapy \[[@CR33]\], which is greater than the EWL (13.0%) in endoluminal plication devices. Sclerotherapy and APC were shown to be less successful in 46.8% of patients when compared to utilisation of endoluminal plication devices (91.8%), and had higher recurrence rates (21.5%).

Complications {#Sec10}
-------------

Six studies reported no complications following procedures involving endoluminal plication devices \[[@CR17], [@CR22], [@CR30], [@CR31], [@CR38], [@CR39]\]. Minor complications reported were abdominal pain (22.5%), sore throat (49.4%), device failure (3.1%), nausea and vomiting (11.0%). A greater range of moderate complications was reported. Specifically, 9.02% of patients reported moderate complications of mucosal tear or damage, 4% reported haematemesis, 2.7% reported bleeding and 10.9% had dysphagia following endoluminal plication. No major complications were reported by any study utilising endoluminal plication devices.

Studies utilising other techniques of sclerotherapy and APC reported minor complication of post-injection pain, abdominal pain and nausea (60%) and moderate complication of mucosal ulceration (35.7%). No major complications were reported.

Outcomes of combination therapy {#Sec11}
-------------------------------

Only two studies assessed the use of combination therapy \[[@CR28], [@CR35]\]. Riva et al.'s study \[[@CR35]\] involved a combination of mucosal ablation and endoscopic suturing using the OverStitch device or mucosal ablation, endoscopic suturing and sclerotherapy, performed following RYGB in 22 patients. Mean pre-revision weight and BMI were 102.3 kg and 42.4 kg/m^2^, respectively. Mean post-revision BMI was reduced by 15.1% at 6 months, and this was increased to 19.8% at 1 year. However, no mean weight or excess weight loss following the revision procedure was reported. In terms of complications, only abdominal pain and nausea were reported (44%).

The other study by Eid \[[@CR28]\] consisted of five patients, in whom a combination of APC and endoscopic suturing (OverStitch device) was performed. Mean pre-revision weight was 110.3 kg and mean pre-revision BMI 37 kg/m^2^. In this group of patients, greatest weight loss was noted 6 months post-procedure (11.0%) and this reduced slightly to 10.1% at 1 year. This is consistent with a fall in 9.1% of mean post-revision BMI measured at 1 year. No complications were reported.

Quality of included studies {#Sec12}
---------------------------

All studies were evaluated for risk of bias using the Newcastle--Ottawa Scale (NOS), which allows for a maximum of eight points, and NIH Quality Assessment Tool (Table [3](#Tab3){ref-type="table"}). A score of 6 or more on the NOS is rated "good", while the NIH tool judges each study to be of "good", "fair" or "poor" quality. Both the NOS and NIH tool assess risk of bias in the selection of cases, outcome assessment and duration of follow-up. Additionally, the NOS assesses the representativeness of the exposed cohort and adequacy of follow-up. Of the 25 observational studies, two studies achieved a score of 7, seven were scored 6, nine rated 5, five scored 4 and two scored 3 on the NOS (Table [3](#Tab3){ref-type="table"}, Supplementary Table [1](#Tab1){ref-type="table"}).Table 3Summary of quality and risk of bias assessment using the Newcastle--Ottawa scale and National Institute of Health quality assessment tool for case series studiesStudyNewcastle--Ottawa scaleNational Institute of Health quality assessment toolOverallMikami et al. \[[@CR14]\]4FairFairManouchehri et al. \[[@CR26]\]6GoodGoodOng'Uti et al. \[[@CR15]\]7GoodGoodGoyal et al. (39)7GoodGoodMullady et al. \[[@CR29]\]5FairFairHorgan et al. \[[@CR16]\]6GoodGoodRyou et al. \[[@CR30]\]4PoorPoorGallo et al. \[[@CR17]\]4FairFairButtelmann et al. \[[@CR31]\]6GoodGoodThompson et al. \[[@CR18]\]5FairFairHeylen et al. \[[@CR27]\]5FairFairPatel et al. \[[@CR32]\]5FairFairTsai et al. \[[@CR22]\]6GoodGoodCatalano et al. \[[@CR33]\]5GoodFairLoewen and Barba \[[@CR34]\]4FairFairJirapinyo et al. \[[@CR24]\]6GoodGoodde Moura et al. \[[@CR39]\]3PoorPoorKumar and Thompson \[[@CR37]\]5FairFairKumar and Thompson \[[@CR36]\]6GoodGoodJirapinyo et al. \[[@CR25]\]5FairFairVargas et al. \[[@CR23]\]5GoodFairBaretta et al. \[[@CR20]\]4FairFairMoon et al. \[[@CR19]\]5FairFairRiva et al. \[[@CR35]\]6GoodGoodEid \[[@CR28]\]3PoorPoor

Twenty-three studies (92%) lacked a comparator group. In all studies, a satisfactory length of follow-up is defined as 12 months or longer---this criteria was met by 20 (80%) studies. Four (15.4%) studies were not awarded an "outcome" score on the Newcastle--Ottawa Scale due to high attrition rates. Eleven (42.3%) studies failed to report the rate of patient follow-up. Two studies in particular \[[@CR14], [@CR16]\] had very low follow-up rate (\< 20%) at 12 months. The authors defined 12 months as the ideal duration of follow-up for post-procedural assessment of weight loss and complications following StomaphyX \[[@CR14]\] and ROSE \[[@CR16]\], respectively, in their selected patients, all of whom were at least 2 years post-RYGB. However, only 15.4% \[[@CR14]\] and 11.2% \[[@CR16]\] were successfully followed up for post-procedural evaluations at 12 months, and the authors did not elaborate the reason(s) behind loss to follow-up.

With regards to the NIH Quality Assessment Tool (Table [3](#Tab3){ref-type="table"}, Supplementary Table 2), 12 (46.2%) studies were subjectively considered to be of "good" quality, while 11 (42.3%) were considered "fair" and three (11.5%) were rated "poor" in the risk of bias assessment. The studies rated "poor" lacked a clear definition for cohort selection and outcome measures, and either failed to describe the results or statistical methods used. Given the high heterogeneity of the studies included in this review, the results and conclusions should be interpreted with caution.

Discussion {#Sec13}
==========

Weight regain is estimated to range between 5--7% \[[@CR2], [@CR4], [@CR5]\] with higher failure rates (20--35%) in the superobese patients (BMI \> 50) \[[@CR6], [@CR40], [@CR41]\]. This systematic review addresses less invasive techniques for treatment of post-operative weight gain and associated short-term outcomes. The use of endoluminal plication devices in revisional surgery is associated with greater initial EWL and fewer complications compared to other techniques (i.e. sclerotherapy, APC) post-RYGB. More specifically, analysis of the included studies has shown successful EWL following the use of endoluminal plication devices in the first 12 months after revisional procedure. This EWL was, however, not well-sustained past 12 months. Greater procedural success and lower recurrence rates are seen in endoluminal plication devices compared to sclerotherapy and APC. Additionally, this review suggests that endoluminal plication devices are associated with lower rates of mild and moderate complications post-procedure compared to sclerotherapy and APC.

Due to the complex nature of weight regain, which involves an interplay between genetic, anatomical, physiological and behavioural factors \[[@CR42], [@CR43]\], there are different theories as to which factor is most predictive of treatment response. Excess weight loss (EWL) following revision surgery using endoluminal plication devices is likely to be due to anatomical reasons. Horgan et al. describes failure of maintenance of EWL to be due to loss of restriction attributed to the enlargement of the gastric pouch, dilatation of gastrojejunostomy and fistula development between gastric pouch and remnant of the stomach \[[@CR16]\]. In this review, Vargas et al.'s study was focused on stoma size reduction, where the revision procedure (TORe) was considered successful if the stoma diameter was reduced to \< 10 mm \[[@CR23]\]. The authors achieved a mean of 70.4% reduction in stoma diameter post-procedure and a resultant mean EWL of 20.2% at 12 months, and 8.0% at 18 months \[[@CR23]\]. Similarly, Jirapinyo et al. showed a mean reduction of 77.3% in stoma diameter post-procedure in their cohort of 25 patients post-procedure (TORe), with a peak mean weight loss of 11.7 kg at 6 months, which later decreased to 10.8 kg at 12 months \[[@CR25]\]. The greater mean EWL in the initial 12 months following the use of endoluminal plication devices in patients post-RYGB which decreased in the ensuing months may be attributed to the lack of durability of endoscopic sutures in the long term \[[@CR44]\]. Follow-up endoscopy after ROSE procedures showed that superior weight loss is associated with reduction in stoma size, with good durability of anchors and tissue fold for up to 12 months post-revision \[[@CR16], [@CR18]\]. These studies provide evidence that stoma size does influence weight loss post-revision surgery, where EWL is greatest in the first 12 months. However, long-term data past 18 months are not recorded for most studies utilising endoluminal plication devices post-RYGB in this review. Future studies, which include follow-up evaluations with endoscopy to verify the link between maintenance of stoma reduction and EWL, are warranted.

Another possible predictor of EWL following revision surgery is ghrelin levels post-procedure. The role of ghrelin in obesity in previous work appears to be significant, however, its exact mechanism requires further investigation \[[@CR45], [@CR46]\]. However, Dayyeh et al. demonstrated a decrease in ghrelin levels in a group of 33 RYGB patients post-sclerotherapy, contrary to what was observed following mechanical endoscopic suturing with endoluminal plication devices \[[@CR42]\]. The authors postulated that ghrelin-producing cells were destructed as a result of sclerosis, hence modulating the neurohormonal signalling to the brain and other organs, altering satiety, food intake behaviours insulin secretion and energy expenditure \[[@CR42], [@CR47]\]. This alteration in neurophysiology may account for the greater sustained EWL over a longer period of time in sclerotherapy compared to endoluminal plication devices. This is because the latter predominantly depends on the reduction in GJ stoma diameter slowing down the activation of gastric wall mechanoreceptors, inhibiting the release of orexigenic gastric peptides such as ghrelin \[[@CR42], [@CR46]--[@CR48]\], which may be less effective compared to a direct destruction of ghrelin-producing cells in sclerotherapy in inducing neurophysiological changes contributing to sustained weight loss.

Theoretically, the modulation in neurohormonal signalling may presumably be applied to APC, but the APC procedures that were utilised in two studies included in this review were aimed at reducing the diameter of the GJ stoma and, therefore, reinitiate weight loss in RYGB patients \[[@CR19], [@CR20]\]. Hence, these studies focused on the anatomical aspect of causes in weight regain, similar to that in endoluminal plication devices, although Moon et al. did demonstrate a sustained mean weight loss up to 24 months, longer than those noted in revisional procedures utilising endoluminal plication devices \[[@CR19]\].

Furthermore, Manouchehri et al. has shown that endoluminal plication devices in revision surgery, specifically the StomaphyX™, can effectively contribute to weight loss in patients following VBG, with only minor complications experienced by patients \[[@CR26]\], although sustained weight loss is not demonstrated due to limited duration of follow-up (3 months). However, the role of endoluminal plication devices is more skewed towards that in RYGB patients because VBG has largely been supplanted by RYGB as a primary bariatric surgery technique in recent years. Nevertheless, outcomes following endoluminal revisional techniques in VBG may still be of interest in a small cohort of patients experiencing weight regain requiring revisional surgery \[[@CR49]--[@CR51]\].

A previous meta-analysis by Vargas et al. has demonstrated the safe and efficacious use of TORe (OverStitch device) in revision surgery performed in RYGB patients \[[@CR23]\]. The present review builds on this finding, and summarises qualitatively the evidence supporting greater long-term post-procedure weight loss when endoscopic suturing with OverStitch device is combined with sclerotherapy or APC, as shown by Riva et al. \[[@CR35]\] and Eid \[[@CR28]\]. Riva et al.'s study was aimed at investigating a possible additive effect of combined sclerotherapy and endoscopic suturing, where the induced fibrosis could enhance the durability of sutures \[[@CR35]\]. Compared with sclerotherapy/APC (EWL 19.9%) or endoluminal plication device (EWL 12.9%) alone, combination therapy is shown to induce the greatest mean EWL of 36.4% at 18 months in a small study of five patients \[[@CR28]\]. Although combination therapy appears to have some benefit in one study, this has not translated to a larger study of 22 patients.

This, compounded by the lack of clear description on patient selection and specification of outcomes, undermines the internal validity of the conclusions. This finding may suggest the potential of combination therapy in managing weight regain following primary bariatric surgery, however, there is currently insufficient evidence to support its superiority over endoluminal plication devices, and vice versa.

Study limitations {#Sec14}
=================

The included studies exhibit some limitations, which must be considered when interpreting the findings of this analysis. Firstly, there is significant variation in primary bariatric procedure, endoluminal revision techniques, methodology of reporting, follow-up times, outcomes and complications. There are limited data on endoscopic revision procedures following sleeve gastrectomy. Given the rapid increase in use of sleeve gastrectomy in recent years, future research on the generalisability and applicability of endoscopic revision surgery in patients with sleeve gastrectomy will be necessary to overcome the inherent limitations of the currently available evidence. Moreover, the heterogeneity of the studies, especially with regards to the selection criteria of patients for revisional surgery, limits the statistical analysis of demographic and procedural variables that appeared to be predictive of maximal weight loss benefit.

Most series have small number of patients and some follow-up data were not available which imposes limits on our ability to make a meaningful conclusion. These high attrition rates could be attributed to a poor understanding of patients' expressed needs, which is central to the development and delivery of effective longer term follow-up care following revision surgery. Studies have shown that patients who did not attend regular follow-up commonly described unmet perceived expectations as well as fear of disappointing the healthcare professional if they were unable to meet nutritional or physical activity targets set \[[@CR52]\].

Additionally, these studies also lacked control of confounding factors including patients' nutritional status, maintenance of diet and exercise, as well as important comorbid conditions such as type 2 diabetes mellitus. Future work may wish to explore the impact of additional routine follow-up addressing these behavioural issues and dietary and lifestyle modifications on maintenance of weight loss. Additionally, all of the studies were conducted in developed countries. These skewed study populations are unlikely to represent faithfully the true populations in less developed countries, thus the generalisability of these findings to the wider population in other parts of the world should be treated with caution. With the majority of studies being retrospective in design and the paucity of studies assessing long-term EWL of greater than 12 months following endoluminal procedures, the question whether endoluminal techniques can sustain long-term EWL still remains. Cohort studies or randomised controlled trials should be performed to not only clarify the role of endoluminal plication devices, but also combination therapy in the management of weight regain following primary bariatric surgery.

Conclusion {#Sec15}
==========

Our study demonstrates the need for detailed discussion and tailoring of techniques and resources to the individual patient. Endoluminal techniques at present affords the patient an opportunity to alter their lifestyle and delay surgical revision or conversion to distal RYGB or biliopancreatic/duodenal switch procedures. However, the paucity of good quality data limits our ability to demonstrate and support the long-term efficacy of endoluminal techniques in the management of weight regain following primary bariatric surgery. However, we suggest that these techniques have an intermediate role in management of weight regain following bariatric surgery, delaying surgical revision or conversion to distal RYGB or biliopancreatic/duodenal switch procedures. Future work is necessary to substantiate the long-term role of endoluminal bariatric procedures in the management of this group of patients.
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